TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT02140255: Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) · Phase: PHASE1/PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 1120 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$299,880

Rescue Site Savings

+$199,920

Unlock Full NCT02140255 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02140255 Rescue Dossier →